Immunocore to present at the Jefferies London Healthcare Conference
November 11, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore to present at the Jefferies London Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 November 2021) Immunocore (Nasdaq:...
Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update Biologics License Application (BLA) and Marketing Authorisation Application (MAA) submissions...
Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
November 09, 2021 08:01 ET
|
Immunocore Holdings Limited
PRESS RELEASE RESS RELEASE Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual...
Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel
October 18, 2021 07:30 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. &...
Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine
September 22, 2021 18:00 ET
|
Immunocore Holdings Limited
Press Release Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine Tebentafusp demonstrated prolonged overall...
Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial
September 20, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated...
Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021
September 13, 2021 16:30 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US...
Immunocore to present at upcoming investor conferences
September 10, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 10 September 2021) Immunocore Holdings plc...
Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
September 08, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma MHRA’s...
Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
August 24, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp...